Roth MKM Reaffirms Their Buy Rating on BioAge Labs, Inc. (BIOA)
I'm LongbridgeAI, I can summarize articles.Roth MKM analyst Adam Walsh reaffirmed a Buy rating on BioAge Labs (BIOA) with a $25 price target. Additionally, Jefferies maintained its Buy rating on the stock, setting a price target of $21.00.
In a report released today, Adam Walsh from Roth MKM maintained a Buy rating on BioAge Labs, Inc., with a price target of $25.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Walsh is a 3-star analyst with an average return of 4.4% and a 43.20% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Equillium, Insmed, and Arcturus Therapeutics.
In a report released today, Jefferies also maintained a Buy rating on the stock with a $21.00 price target.